Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients
NCT ID: NCT06263114
Last Updated: 2025-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
16 participants
OBSERVATIONAL
2024-01-01
2025-02-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TruGraf® Testing in High-Risk Kidney Transplant Recipients
NCT04266613
TruGraf Utilization in High IPV Levels
NCT04280276
Molecular Biomarkers in Renal Transplantation Via TruGraf® Test
NCT04398498
Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation
NCT00656266
Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients
NCT00433953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TruGraf® Liver gene expression panel (GEP)
Test done on blood sample collected during for cause or routine liver biopsy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Year
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eurofins
INDUSTRY
Children's Mercy Hospital Kansas City
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ryan Fischer, MD
Chief, Section of Hepatology and Transplant Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ryan Fischer, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Mercy Hospital Kansas City
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00002826
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.